INC Research Holdings, a global phase I to IV CRO, has been named the recipient of Medidata’s Trial of the Future Award in the Operational Excellence category. Medidata is a global provider of cloud-based solutions for clinical research in life sciences.
“The Medidata Trial of the Future Award is a strong testament to INC’s ability to leverage the latest technologies to help our customers develop new medicines as quickly, efficiently and safely as possible,” said INC Research CEO Jamie Macdonald. “Our longstanding relationship with Medidata and the use of its Clinical Cloud platform is one of the ways INC stays at the forefront of operational excellence in providing our customers with access to the data they need to accomplish their clinical development goals.”
The award celebrates excellence in advancing drug development and the delivery of innovative new therapies to market. In its inaugural year, the Trial of the Future Awards honor life sciences companies excelling in four categories: innovation, operational excellence, technology and collaboration.
INC Research was recognized for its efficient use and adoption of technology and analytics within Medidata’s integrated cloud solution for electronic data capture (Medidata Rave) and operational clinical trial management (Medidata CTMS), bringing immediate benefits to its pharmaceutical and biotechnology customers.